Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

Exscientia Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	6,662	7,292	8,206	8,231	6,892	6,590
Other Revenue	14.25	14.25	16.23	17.87	15.33	13.64
Revenue	6,676	7,307	8,222	8,249	6,908	6,604
Revenue Growth (YoY)	-18.12%	-11.13%	-0.33%	19.42%	4.60%	-5.58%
Cost of Revenue	3,173	3,804	4,632	4,992	4,161	4,024
Gross Profit	3,503	3,503	3,590	3,258	2,747	2,580
Selling, General & Admin	2,424	2,459	2,508	2,347	1,930	1,815
Research & Development	163.42	162.38	184.63	153.15	161.05	149.2
Other Operating Expenses	68.31	63.44	57.28	76.69	64.12	58.29
Operating Expenses	2,700	2,729	2,769	2,586	2,160	2,029
Operating Income	802.57	774.04	821.03	671.32	587.04	551.04
Interest Expense	-36.02	-40.2	-35.85	-10.27	-2.94	-0.01
Interest & Investment Income	1,909	1,937	362.75	330.35	263.97	188.48
Currency Exchange Gain (Loss)	-1.51	-1.51	-1.13	-2.44	0.69	1.73
Other Non Operating Income (Expenses)	-1.8	-2.55	-2.71	3.63	-5.3	-6.27
EBT Excluding Unusual Items	2,672	2,666	1,144	992.59	843.46	734.98
Impairment of Goodwill	-53.61	-53.61	-18.78	-19.57	-	-
Gain (Loss) on Sale of Assets	0.15	0.07	-0.48	0.67	10.39	6.62
Asset Writedown	-67.51	-60.16	-24.95	-0.18	-	-
Other Unusual Items	24.07	26.13	-4.51	6.67	18.96	26.46
Pretax Income	2,575	2,579	1,095	980.19	872.81	768.06
Income Tax Expense	371.31	363.56	126.66	106.93	85.93	88.4
Earnings From Continuing Operations	2,204	2,215	968.71	873.26	786.88	679.66
Minority Interest in Earnings	12.63	14.12	18	-11.46	-17.73	-17.96
Net Income	2,216	2,229	986.71	861.79	769.14	661.7
Net Income to Common	2,216	2,229	986.71	861.79	769.14	661.7
Net Income Growth	127.72%	125.94%	14.49%	12.05%	16.24%	5.78%
Shares Outstanding (Basic)	766	769	771	769	769	769
Shares Outstanding (Diluted)	769	771	771	776	769	769
Shares Change (YoY)	-0.41%	0.07%	-0.71%	0.94%	-0.04%	-0.37%
EPS (Basic)	2.89	2.90	1.28	1.12	1.00	0.86
EPS (Diluted)	2.88	2.89	1.28	1.11	1.00	0.86
EPS Growth	128.66%	125.78%	15.32%	11.00%	16.28%	6.17%
Free Cash Flow	1,242	806.86	547.56	569.34	695.45	482.26
Free Cash Flow Per Share	1.62	1.05	0.71	0.73	0.90	0.63
Dividend Per Share	1.280	1.280	1.280	1.120	0.500	0.300
Dividend Growth	-	-	14.29%	124.00%	66.67%	-
Gross Margin	52.47%	47.94%	43.66%	39.49%	39.77%	39.07%
Operating Margin	12.02%	10.59%	9.98%	8.14%	8.50%	8.34%
Profit Margin	33.20%	30.51%	12.00%	10.45%	11.13%	10.02%
Free Cash Flow Margin	18.60%	11.04%	6.66%	6.90%	10.07%	7.30%
EBITDA	919.85	893.19	947.65	786.15	701.29	660.9
EBITDA Margin	13.78%	12.22%	11.53%	9.53%	10.15%	10.01%
D&A For EBITDA	117.28	119.15	126.62	114.83	114.25	109.85
EBIT	802.57	774.04	821.03	671.32	587.04	551.04
EBIT Margin	12.02%	10.59%	9.98%	8.14%	8.50%	8.34%
Effective Tax Rate	14.42%	14.10%	11.56%	10.91%	9.84%	11.51%
Revenue as Reported	6,676	7,307	8,222	8,249	6,908	6,604
Advertising Expenses	-	445.36	437.2	-	321.16	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.